

Desensitization of the P2X₂ receptor controlled by alternative splicing

U. Brändle^a, P. Spielmanns^d, R. Osteroth^b, J. Sim^c, A. Surprenant^c, G. Buell^c,
J.P. Ruppersberg^b, P.K. Plinkert^a, H.-P. Zenner^a, E. Glowatzki^{a,b,*}

^aDepartment of Otolaryngology, University of Tübingen, Röntgenweg 11, 72076 Tübingen, Germany

^bInstitute of Physiology II, University of Tübingen, Gmelinstr. 5, 72076 Tübingen, Germany

^cGeneva Biomedical Research Institute, Glaxo Wellcome Research and Development S.A., 14 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland

^dMerz GmbH and Co., Eckenheimer Landstr. 100–104, 60318 Frankfurt/Main, Germany

Received 23 December 1996; revised version received 24 January 1997

Abstract P2X receptors are ion channels gated by extracellular ATP. We report here cloning of a P2X₂ receptor splice variant (P2X₂₋₂) carrying a 207 bp deletion in the intracellular C-terminus and the analysis of the corresponding genomic structure of the P2X₂ gene. P2X₂₋₂ is as highly expressed as the original P2X₂ sequence in various tissues. ATP-activated currents mediated by heterologous expressed P2X₂ or P2X₂₋₂ receptors showed significant differences in desensitization time constants and steady-state currents in the continuous presence of ATP. These results imply functional differences between cells differentially expressing these P2X₂ isoforms.

© 1997 Federation of European Biochemical Societies.

Key words: P2X receptor; Genomic sequence; Alternative splicing; Desensitization

1. Introduction

P2X receptors are ion channels gated by extracellular ATP. They are expressed in a broad variety of tissues and known to mediate fast synaptic transmission [7,8] and synaptic transmission between sympathetic nerves and smooth muscle [9,19]. By now 7 P2X receptor subunits (P2X₁–P2X₇) have been cloned which share a putative two-transmembrane segment structure with intracellular C- and N-termini and an extracellular loop [2,3,5,6,14,20,21]. Heterologous expression of each subunit results in the formation of non-selective cation channels with differential sensitivities for the agonists ATP and α,β -methylene-ATP and the antagonists pyridoxal-5-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) and suramin. They also differ in their time constant of desensitization: P2X₁ and P2X₃ are fast desensitizing while P2X₂ and P2X₄ to P2X₇ show a much slower desensitization.

Here we report the cloning of a splice variant (P2X₂₋₂) of the P2X₂ receptor subtype and the identification of the corresponding rat genomic sequence. We used heterologous expression of the P2X₂ and P2X₂₋₂ receptor to look for functional differences between both isoforms.

2. Materials and methods

2.1. RT-PCR analysis

Total RNA from brain, spleen, kidney, intestine and organ of Corti was isolated from adult Wistar rats (Charles River, Germany) with the RNeasy Total RNA-Kit (Qiagen, Chatsworth, CA). First strand

cDNA was synthesized from 1 μ g total RNA using an oligo d(T) primed 20 μ l reaction by the Superscript RNase H-Reverse transcriptase (Life Technologies Inc., Gaithersburg, MD) under standard conditions [1].

PCR amplification of a P2X₂-specific fragment was performed using the following primers: sense primer (up2: 5'-ATTCGCA-CAGGGCACTGTGTACC-3', positions 424–446) and antisense primer (lo2: 5'-TTAGCAGCCAAAGCTGTCTCT-3', positions 1460–1480) resulting in a 1056 bp fragment. Nested PCR: sense primer (up3: 5'-GCCTGGTGGCCGGTGGAG-3', positions 484–501), antisense primer (lo2) resulting in a 955 bp fragment.

The PCR amplifications were performed on a GeneAmp PCR System 9600 thermal cycler (Perkin Elmer, Norwalk, CT) under standard conditions [18] using 1 μ l of the first strand cDNA in a final volume of 50 μ l, 1 U AmpliTaq (Perkin Elmer) and a primer concentration of 40 ng/ μ l. Reaction conditions for the first and second round of amplification were 45 cycles of 30 s 94°C, 30 s 60°C and 30 s 72°C starting with 3 min at 94°C and ending with an extension of 5 min at 72°C. The reaction products were at first analyzed by gel electrophoresis. Identity of the PCR products was tested by Southern blot analysis using a 165 bp PCR fragment of the P2X₂ receptor sequence as a hybridization probe (positions 519–684). In addition PCR products were gel-isolated and, after blunting with kinase, subcloned in an *EcoRV* cut, dephosphorylated pBluescript vector (Stratagene, La Jolla, CA). Sequences of the recombinant fragments were determined on both strands by fluorescent DNA sequencing (Applied Biosystems Inc., Foster City, CA).

2.2. Genomic organization of the P2X₂ receptor gene

Genomic DNA was isolated from rat liver using the QIAamp Tissue Kit (Qiagen, Chatsworth, CA). To identify the genomic P2X₂ receptor sequence two overlapping fragments were amplified from the start codon to 61 bp downstream of the stop codon (3'UT region) of the published P2X₂ receptor sequence [2]. The primer pair for the amplification of the 5' fragment was: sense primer (up1: 5'-GCCATGGTCCGGCGCTT-3', bp –3–14) and antisense primer (lo1: 5'-GGCTGACACCTCGCAGGTCTT-3', bp 466–486); to amplify the second fragment the primer pair up2/lo2 (as described in Section 2.1) was used. The PCR conditions were 45 cycles of 1 min 94°C, 1 min 60°C and 1 min 72°C starting with 3 min at 94°C and ending with an extension of 5 min at 72°C. The fragments were subcloned as described in Section 2.1. The recombinant cloned DNA was denatured by NaOH and sequenced on both strands using Sequenase Version 2.0 Kit (Amersham/USB, Cleveland, OH). For both fragments 10 independent clones were analyzed, showing identical sequences.

2.3. Expression of P2X₂ isoforms in *Xenopus* oocytes and HEK293 cells

For functional expression a full-length P2X₂₋₂ receptor clone was constructed. The *HpaI/XhoI* restriction fragment of the original P2X₂ receptor clone [2] in pcDNA 3 (Invitrogen, San Diego, CA) was substituted by the corresponding fragment of the subcloned isoform carrying the deletion. The identity of the resulting P2X₂₋₂ clone was verified by sequencing.

Capped cRNAs specific for P2X₂ and P2X₂₋₂ were synthesized *in vitro* using T7 polymerase (Stratagene capping kit) and injected into *Xenopus* oocytes.

Handling and injection of *Xenopus* oocytes has been described previously [10]. 24 h after injection oocytes were treated with collagenase

*Corresponding author. Fax: (49) (7071) 22917.
E-mail: Elisabeth.Glowatzki@Uni-Tuebingen.de

type II (Sigma, 0.5 mg/ml) for 45 min. After collagenase treatment the follicle cell layer was removed manually with fine forceps. Oocytes were defolliculated carefully as follicular oocytes are known to have intrinsic P2 receptors [12]. Not injected defolliculated oocytes from every donor animal were tested for endogenous ATP-activated currents which have been described previously to be activated at agonist concentrations $> 100 \mu\text{M}$ [12,13]. Similar to the observations of King et al. [12] we found these endogenous ATP-activated currents in only one batch of oocytes excised from one of 20 donor frogs. This batch of oocytes was not used. Electrophysiological recordings were performed 3–7 days after injection using a two-microelectrode voltage clamp. Current and voltage electrodes were pulled from thick-walled borosilicate glass. They were filled with 3 M KCl and had resistances between 0.1 and 0.5 M Ω . Currents were recorded with a TurboTec 01C amplifier (npi, Tamm, Germany), digitized at 30 Hz (ITC16, HEKA, Lamprecht, Germany) and stored on the hard disk. The bath chamber was made up as a narrow canal to achieve complete solution exchanges in less than 3 s. The extracellular solution was composed of (in mM): NaCl 115, KCl 2.5, MgCl₂ 1.8, HEPES 10; pH adjusted to 7.3 with NaOH. All experiments were performed at room temperature (approximately 23°C). To exclude that the decline of current during ATP application is due to a channel block mediated by extracellular divalent cations, we elicited ATP-activated currents in an extracellular solution with the divalent cations substituted by polyvinylpyrrolidone (Boehringer Mannheim) [16]. Under these conditions the ATP-activated currents declined with the same time course as in extracellular solutions containing Ca²⁺ or Mg²⁺.

The HEK293 cells were transiently transfected with the cDNA encoding P2X₂ or P2X₂₋₂ using lipofectin (Life Technologies Inc.) as previously described [14]. Conventional whole-cell recording and fast-flow U-tube agonist application methods were used. Internal pipette solution was (mM): KCl, K-aspartate or Cs-aspartate 140, NaCl 20, EGTA 10 and HEPES 5. Extracellular solution was (mM): NaCl 147, KCl 2, CaCl₂ 2, MgCl₂ 1, HEPES 10 and glucose 12; pH was adjusted to 7.35 with NaOH. ATP (magnesium salt), α , β -methylene-ATP (lithium salt) and PPADS were purchased from Sigma (St. Louis, MO) and suramin from Bayer (Leverkusen, Germany).

3. Results

3.1. Detection and cloning of the P2X₂₋₂ receptor isoform

Various rat tissues were tested for P2X₂ receptor expression with PCR using a P2X₂-specific primer pair (up2/lo2) (Fig. 1A). The PCR products resulted in three distinct bands of 995 bp, 910 bp and 790 bp length in the gel electrophoresis. All three bands showed hybridization with a P2X₂-specific probe in Southern blot analysis. For identification of the sequences the fragments were isolated, subcloned and sequenced. The largest band with 995 bp yielded the original P2X₂ sequence [2].

The smallest band with 790 bp revealed a 207 bp in-frame deletion in the C-terminal region at nucleotide positions 1111–1317 of the original P2X₂ sequence (Fig. 2).

Similarly, a RT-PCR reaction on brain RNA with primers (up1/lo2) covering the whole coding region of P2X₂, besides the expected 1483 bp fragment, yielded an approximately 200 bp shorter fragment (not shown). This suggests that the 207 bp deletion is a naturally occurring variant of the P2X₂ receptor possibly generated by alternative splicing.

Subcloning and sequencing of the intermediate band yielded either the sequence of the original or that of the 207 bp deleted form. Control PCRs with cloned DNA of the original P2X₂ sequence and the 207 bp deletion mixed in a 1:1 relation also resulted in three bands in gel electrophoresis. Therefore we interpret this band as a PCR artefact (Fig. 1B; see Section 4).

3.2. Genomic structure of the P2X₂ receptor gene

To obtain the genomic organization and putative splice sites




Fig. 1. A: Tissue distribution of P2X₂ isoforms detected by RT-PCR. The PCR yielded three products with 995 bp, 910 bp and 790 bp fragment length, respectively. The positive control was cloned P2X₂ DNA. As marker a 100 bp ladder was used. B: PCR using a mixture of the cloned P2X₂ sequence and the 207 bp deleted isoform resulted in the same 3 fragments as in A.

A

```

ATG GTC CCG CGC TTG GCC CGG GGC TGC TGG TCC CGC TTC TGG GAC TAC GAG ACG CCT AAG GTG ATC GTG GTG CGG AAT CGG CGC CTG GGA TTC GTC 96
M V R R L A R G C W S A F W D Y E T P K V I V V R N R R L G F V
      TM1 138
CAC CGC ATG GTG CAG CTT CTC ATC CTG CTT TAC TTC GTG TG gTgcgcgggcccggggcgacgtggcggtcggggagggggatcctcaactgggcttgagagccttagg 209
H R M V Q L L I L L Y F V W
      274
gcttcaggaggggacatccagggtctctccagggttgcctcgggaccgcccctgtcccacag G TAC GTC TTC ATC GTG CAG AAA AGC TAC CAG GAC ACC GAG ACC GGA 320
      Y V F I V D K S Y Q D S E T G
      409
CCG GAG AGC TCC ATC ATC ACC AAA GTC AAG GGG ATC ACC ATG TCG GAA GAC AAA GTG TGG GAC GTG GAG GAA TAC GTA AAG CCC CGG G cccacgtct 417
P E S S I I T K V K G I T M S E D K V W D V E E Y V K P P E
      604
ttatttcccccccccagcagctcgagtgagtggtcagtggtgcctcctctgtagaccgaccccctctctcggggctggg AG GGG GGC AGT GTA GTC ACC ATC ATC ACC 533
      G G S V V S I I T
      679
AGG ATC GAG GTT ACC CCT TCC CAG ACC TTG GGA ACA TGC CCA GAG gTgaggggggtcaagggcggtctgggaaacctaaagccagttacagagtctacctgcacctacagt 645
R I E V T P S D T G G T C P E
      656 734
ctccacttttag AGC ATG AGG GTT CAC AGC TCT ACC TGC CAT TCA GAC GAC GAC TGT ATT GCC GGA CAG CTG GAC ATG CAA GGC AAT GG gTcagtgTgcac 745
      S H R V H S S T C H S D D D C I A G Q L D M Q G N G
      811 up2
cagggcagtggtggagggcggttagcacagacctcagcagattaacagtgTgTgctcttag G ATT CGC ACA GGG CAC TGT GTA CCC TAT TAC CAT GGG GAC TCC AAG 857
      I R T G H C V P Y Y H G D S K
      908
ACC TGC GAG GTG TCA GCC TGG TGC CCG GTG GAG GAT GGA ACT TCT GAC AA gTaatgcaggatcccacagcccattgtcagttctctctctactgatgaagatcag 967
T C E V S A W C P V E D G T S D N
      1060
attogctgggggggggggggggagaccatccctccctctctccgggactttggggaaaggagattaacacctgttctgtacctttacag C CAT TTT CTG GGT AAA ATG GCC CCA 1085
      H F L G K H A P
      1142
AAT TTC ACC ATC CTC ATC AAG AAC AGC ATC CAC TAC CCC AAG TTC AAG TTC TCA AA gTgagctgagggcagagatcaaatgtctgccactgtgtaggtttgtct 1193
N F T I L I K N S I H Y P K F K F S K
      1242
ggagccagggttttagttagcaggtctgtgctctctgcacctcttag G GGC AAC ATT GCA AGC CAG AAG AGT GAC TAC CTC AAG CAT TGC ACA TTT GAT CAG GAC 1300
      G N I A S Q K S D Y L K H C T F D Q D
      1382
TCT GAC CCA TAC TGT CCC ATC TTC AGG CTG GGT TTC ATT GTT GAG AAG GCA GGA GAG AAC TTC ACA GAA CTG GCA CAC AAG gTgagggccaaagggcatgg 1401
S D P Y C P I F R L G F I V E K A G E N F T E L A H K
ggacagagaagctgggtgccagcatctgtaccgggaoggttttactgcactatagatgctccctctttgttttgctgctttagctgggttttaggcagaggggagaatgtgattatggtctggc 1529
aggcaactgctcaattattgatactctgtctatgactgggtctagctacctgcctatgcctccaaagccagagagtcactgttccctggaccctttgactctgagctgaacctaccctcaggtttg 1657
tctgctctgtctctcaacctccttgcttactttctgcag GGC GGT GTC ATT GGA GTC ATC ATC AAC TGG AAC TGT GAC CTG GAC TTG TCT GAA TCA GAG TGC 1764
      G G V I G V I I N W N C D L D L S E S E C
      1833
AAC CCC AAA TAT TCT TTC CGG AGG CTC GAC CCC AAG TAT GAC CCT GCC TCC TCA GGC TAC AAC TTC AG gTaccctgttccctgaaatgtctggatcatgacatag 1869
N P K Y S F R R L D P K Y D P A S S G Y N F R
      1994
ccagtgatggtgggtgctgattctagttacaccagaatggcctggaagagaggaagtgagtgctcaaatgccacagctctcagaatgacagcttcaacccacctctggttctccacctag G 1995
      2089
TTT GCC AAG TAT TAC AAG ATA AAC GGC ACT ACC ACC ACT CGA ACT CTC ATC AAA GCC TAT GGG ATT CGA ATC GAT GTT ATC GTG CAT GGA CAG gTat 2092
F A K Y Y K I N G T T T T R T L I K A Y G I R I D V I V H G Q
gcacatctgaaggggtgcttaggtctgtctgctgggtgctcaggtgctccctctatagatccccccttagctccctttctgccaaagcagccccgtgTcgaaggtttcaacaaatgaagctggtg 2220
ctctacag GCA GGG AAA TTC AGT CTC ATT CCC ACC ATC ATC AAT CTG GCC ACT GCT CTG ACC TCC ATC GGG GTC gTaaagaaatccaaactcccttggggatctgg 2325
      A G K F S L I P T I I N L A T A L T S I G V
      2379
gtcaggtaggaggtgtttggtaggcctctaccacctggaactgctgacttag GGC TCC TTC CTG TGT GAC TGG ATT TTG TTA ACG TTC ATG AAC AAA AAC AAG CTC 2433
      G S F L C D W I L L T F H N K N K L
      spliced region
TAC ACC CAT AAG AAG TTC GAC AAG GTG GGT ACT CCA AAG CAT CCC TCA AGT AGA TGG CCT GTG ACC CTT GCC CTT GTC TTG GGC CAG ATC CCT CCC 2529
Y S H K K F D K V R T P K H P S S R W P V T L A L V L G Q I P P
CCA CCT AGT CAC TAC TCC CAG GAT CAG CCA CCC AGC CCT CCA TCA GGT GAA GGA CCA ACT TTG GGA GAA GGG GCA GAG CTA CCA CTG GCT GTC CAG 2625
P P S H Y S Q D Q P P S P P S G E G P T L G E G A E L P L A V Q
TCT CCT CGG CCT TGC TCC ATC TCT GCT CTG ACT GAG CAG GTG GTG GAC ACA CTT GGC CAG CAT ATG GGA CAA AGA CCT CCT GTC CCT GAG CCT TCC 2721
S P R P C S I S A L T E Q V V D T L G Q H M G Q R P P V P E P S
      1a2
CAA CAG GAC TCC ACA TCC ACG GAC CCC AAA GGT TTG GCC CAA CTT TGA tctcactcactaaactccagacctggacctggggaagccagagacagcttttggctgtaa 2830
Q Q D S T S T D P K G L A Q L

```




Fig. 2. A: Genomic structure of the rat P2X₂ gene. Eleven exons are shown with deduced amino acid sequences indicated below. The exon-intron borders are indicated by the corresponding base pair numbers, the 10 intron sequences are written in small letters. The transmembrane domains TM1 and TM2 and the spliced region of the P2X₂₋₂ isoform are shown in frames. The positions of primers are indicated by arrows. The sequence has been deposited in the EMBL data base under accession number Y09910. B: Organization of the P2X₂ receptor gene. The position of the introns (I–X) is indicated by the nucleotide number of the P2X₂ receptor coding region (A of ATG = 1). The putative transmembrane domains (TM1 and TM2) and the deleted region of the P2X₂₋₂ isoform are indicated.

of the P2X₂ receptor gene we amplified two overlapping PCR fragments covering the coding region of the rat P2X₂ receptor gene (Fig. 2A). The resulting genomic sequence with 2830 bp compared to 1481 bp of the P2X₂ receptor cDNA includes 10 introns ranging in size from 78 to 320 bp, most of them in the 100 bp range (Fig. 2B). Interestingly, the 207 bp deletion of the P2X₂ receptor isoform, which we detected in various tissues coexpressed with the P2X₂ receptor, is not flanked by introns but by consensus sequences for splice sites which induce splicing of a fragment directly out of an exon [15].

3.3. Functional expression of the P2X₂₋₂ receptor

Both isoforms of the P2X₂ receptor were expressed in *Xenopus* oocytes and HEK293 cells. Fig. 3 shows ATP-activated currents investigated in defolliculated oocytes with the two-microelectrode voltage clamp technique at a holding potential of -70 mV.

300 μ M ATP applied for 1 min elicited inward currents with amplitudes of 2.1 ± 1.0 μ A (mean \pm S.D.; $n = 8$) in P2X₂ injected oocytes and of 5.5 ± 3.1 μ A ($n = 12$) in P2X₂₋₂ injected oocytes. Comparing the ATP-activated currents of both clones we found a significantly faster desensitization of the P2X₂₋₂ receptor with desensitization time constants of $\tau = 12 \pm 1$ s ($n = 12$) compared to the P2X₂ receptor with $\tau = 56 \pm 6$ s ($n = 8$) ($P < 10^{-7}$ revealed by Student's *t*-test).

Steady-state current amplitudes of the ATP-activated currents (I_s ; measured as remaining current amplitude compared to the maximum current amplitude) were evaluated during application of 300 μ M ATP for 5–15 min. P2X₂ receptor currents desensitized to steady-state currents of $I_s = 7.4 \pm 3.4\%$ ($n = 9$) whereas P2X₂₋₂ receptor currents desensitized to significantly smaller current amplitudes of $I_s = 0.9 \pm 0.3\%$ ($n = 8$) ($P < 0.0005$).

The pharmacological properties of the P2X₂₋₂ receptor were measured in HEK293 cells using whole-cell recording at a holding potential of -75 mV. There was no obvious difference compared with the P2X₂ receptor. ATP induced concentration-dependent inward currents with a maximal response observed at 300 μ M; half-maximal concentration (EC₅₀ value) was 7.8 ± 2.1 μ M and Hill slope was 1.7 ± 0.12 (mean \pm S.E.M.; $n = 9$). α, β -Methylene-ATP (10–300 μ M) was virtually inactive as an agonist at this receptor. Currents in-

duced by 30 μ M ATP were inhibited nearly completely by suramin (1–10 μ M) and PPADS (10 μ M).

4. Discussion

In this paper we describe cloning and functional expression of the splice variant P2X₂₋₂ of the P2X₂ receptor characterized by a 207 bp deletion in the C-terminus. We also report the cloning of the P2X₂ receptor genomic sequence which consists of 11 exons comprising the published cDNA sequence [2] and 10 introns (Fig. 2B). Analysis of splice donor and acceptor sequences showed that all intronic sequences except that of intron II fit to the extended GT-AG rule with the consensus sequences $C/AAG|GT^A/GAGT$ (for splice donor sequence) and $(T/C)_nN^C/TAG|G$ (for splice acceptor sequence) [15]. In the P2X₂ receptor genomic sequence the 207 bp deletion in the C-terminus is not flanked by any intronic sequence but the splice junction sites of the deleted fragment are flanked by sequences fitting to the extended GT-AG rules. The 207 bp deletion is spliced out of a genomic region which codes for an exon of the P2X₂ receptor.

A recently published truncated form of the P2X₂ receptor [11] carries a 85 bp insertion containing a stop codon which is identical to intron X of the genomic sequence. This isoform was detected in pituitary gland and stria vascularis of the inner ear, but no functional expression has been shown. However, the large number of exon-intron borders suggests the existence of further P2X₂ receptor splice variants.

P2X₂-specific RT-PCR yielded the P2X₂ and P2X₂₋₂ fragments and a third band of 910 bp length besides. Neither subcloning nor direct sequencing of this band repeated for several times resulted in any sequence information with the expected size. The 910 bp band could not be eliminated by changing PCR conditions. Different annealing temperatures, numbers of PCR cycles and primer concentrations have been tested. Control PCRs using a mixture of cloned P2X₂ and P2X₂₋₂ DNA also resulted in three bands (Fig. 1B). Therefore we suggest that the 910 bp band may represent an artefact created by an interaction of the P2X₂ isoforms.

All tissues tested in this study using RT-PCR showed an expression of both isoforms (Fig. 1A) with a tendency to a stronger expression of the P2X₂₋₂ receptor.

Functional comparison of the P2X₂ and P2X₂₋₂ variants




Fig. 3. Functional expression of the P2X₂₋₂ receptor and comparison with P2X₂. 300 μM ATP elicited inward currents which differed significantly in time constants of desensitization (mean ± S.D.) between the two isoforms. The recordings were made in *Xenopus* oocytes with two-electrode voltage clamp at a holding potential of -70 mV.

revealed significant differences. ATP-activated currents mediated by the P2X₂₋₂ receptor desensitized faster than P2X₂-mediated currents. Desensitization was nearly complete for the P2X₂₋₂ receptor ($0.9 \pm 0.3\%$) whereas the P2X₂ receptor desensitized to a steady-state level of $7.4 \pm 3.4\%$. Thus P2X₂ rather than P2X₂₋₂ receptors mediate a steady Ca²⁺ influx in the presence of ATP. This may represent a remarkable functional difference between cells expressing either of the two P2X₂ isoforms. Differential expression of the P2X₂ and P2X₂₋₂ variants needs further investigation since in earlier studies probes for in situ hybridization, Northern blot analysis or antibody staining did not discriminate between them [2,11,14].

Besides the large difference in desensitization observed between the two splice variants we observed smaller but also significant differences between different batches of oocytes. This might be explained by a different level of second messenger regulation of the P2X receptors in different oocyte batches. There are several putative PKA/PKC regulation sites in the N-terminal and C-terminal regions of the P2X receptor sequence which might account for these effects. Some of these plus one proline-rich region with an SH3 binding motif for the association to cytoskeletal proteins [17] are localized within the 207 bp domain spliced out in P2X₂₋₂ which is located in the C-terminal intracellular region of the protein.

Coexpression of the P2X₂ and the P2X₃ receptor has been shown in dorsal root ganglion sensory neurons which transmit nociception [4,14]. Intermediate time courses of desensitization in ATP-activated currents measured in sensory neurons have been explained by heteromultimerization of P2X₂ and P2X₃. Such time courses might also be explained by an involvement of the P2X₂₋₂ receptor. Therefore, to understand the basis of important physiological processes like nociception the expression pattern, possible heteromultimerization and regulation of the P2X₂ receptor isoforms need further detailed investigation.

Acknowledgements: We thank A. Brake and D. Julius for P2X₂ DNA, Mrs. C. König and Mrs. H.-S. Geisler for their excellent technical assistance in molecular cloning, sequencing and RNA synthesis. This work was supported by the Deutsche Forschungsgemeinschaft

(KliFo Hörforschung Ze 149/6-1) and a bursarship for U. Brändle by the Ciba Foundation, London.

References

- [1] Ausubel, F., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (1995) Short Protocols in Molecular Biology, Wiley and Sons, Chichester.
- [2] Brake, A.J., Wagenbach, M.J. and Julius, D. (1994) Nature 371, 519–523.
- [3] Buell, G., Lewis, C., Collo, G., North, R.A. and Surprenant, A. (1996) EMBO 15, 55–62.
- [4] Burnstock, G. and Wood, J.N. (1996) Curr. Opin. Neurobiol. 6, 526–532.
- [5] Chen, C., Akoplan, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G. and Wood, J.N. (1995) Nature 377, 428–431.
- [6] Collo, G., North, R.A., Kawashima, E., Merlo-Pich, E., Neidhart, S., Surprenant, A. and Buell, G. (1995) J. Neurosci. 16, 2495–2507.
- [7] Edwards, F.A., Gibb, A.J. and Colquhoun, D. (1992) Nature 1992, 144–147.
- [8] Evans, R.J., Derlach, V. and Surprenant, A. (1992) Nature 357, 503–505.
- [9] Evans, R.J. and Surprenant, A. (1992) Br. J. Pharmacol. 106, 242–249.
- [10] Fakler, B., Herlitz, S., Amthor, B., Zenner, H.-P. and Ruppersberg, J.P. (1994) J. Biol. Chem. 269, 16187–16194.
- [11] Housley, G.D., Greenwood, D., Bennet, T. and Ryan, A.F. (1995) Biophys. Biochem. Res. Commun. 212, 501–508.
- [12] King, B., Wang, S. and Burnstock, G. (1996) J. Physiol. 494, 17–28.
- [13] Kupitz, Y. and Atlas, D. (1993) Science 261, 484–486.
- [14] Lewis, C., Neidhart, S., Holy, C., North, R.A., Buell, G. and Surprenant, A. (1995) Nature 377, 432–435.
- [15] Mount, S.M. (1982) Nucleic Acids Res. 11, 459–472.
- [16] Raditsch, M. and Witzeman, V. (1994) FEBS Lett. 354, 177–182.
- [17] Rotin, D., Bar-sagi, D., O'Brodivich, H., Merilainen, J., Letho, V.P., Canessa, C.M., Rossier, B.C. and Downey, G.P. (1994) EMBO J. 13, 4440–4450.
- [18] Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. and Arnheim, N. (1985) Science 230, 1350–1354.
- [19] Surprenant, A., Buell, G. and North, R.A. (1995) Trends Neurol. Sci. 18, 224–229.
- [20] Surprenant, A., Rassendren, F., Kawashima, E., North, R.A. and Buell, G. (1996) Science 272, 735–738.
- [21] Valera, S., Hussy, N., Evans, R.J., Adami, N., North, R.A., Surprenant, A. and Buell, G. (1994) Nature 371, 516–519.